Peer-reviewed veterinary case report
Pancreatic enzyme levels in cats with chronic kidney disease
By Xenoulis, Panagiotis G et al.·Published in Journal of veterinary internal medicine·2021·Texas A&M University, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Serum feline pancreatic lipase immunoreactivity and trypsin-like immunoreactivity concentrations in cats with experimentally induced chronic kidney disease.
- Species:
- cat
Plain-English summary
A group of cats with chronic kidney disease (CKD) had their blood tested for pancreatic enzymes to see how kidney problems might affect the results. The study found that the levels of one enzyme, trypsin-like immunoreactivity (fTLI), were significantly higher in these cats compared to healthy cats, which could complicate diagnosing pancreatic issues. However, the other enzyme, pancreatic lipase immunoreactivity (fPLI), was not affected by CKD, meaning it can still be used to diagnose pancreatitis in cats with kidney disease. This information is important for veterinarians when evaluating cats with both conditions.
People also search for: cat kidney disease symptoms · cat pancreatitis diagnosis · elevated fTLI in cats · chronic kidney disease in cats · cat blood test results explained
Abstract
BACKGROUND: Serum feline pancreatic lipase immunoreactivity (fPLI) and trypsin-like immunoreactivity (fTLI) concentrations are commonly used in cats for the evaluation of pancreatic disease. The effect of kidney disease on these tests in cats are unknown. OBJECTIVE: To investigate the effect of experimentally induced chronic kidney disease (CKD) on serum fPLI and fTLI concentrations. ANIMALS: Surplus serum samples from 20 cats with CKD experimentally induced for an unrelated project and a group of healthy control cats. METHODS: Serum fTLI and fPLI concentrations were compared between groups. RESULTS: Mean (±SD) serum fTLI concentrations in 20 cats with CKD (117.8 ± 63.6 μg/L) were significantly higher than those in healthy cats (n = 32; 46.9 ± 17.5 μg/L; P < .0001). Serum fTLI concentrations in cats with CKD were above the upper limit of the reference interval in 13 of 20 cats (65%). Serum fPLI concentrations were not significantly different between cats with induced CKD (n = 18; 8.6 μg/L; range, 5.4-9.9 μg/L) and healthy cats (n = 41; 7.4 μg/L; range, 5.0-15.2 μg/L; P = .12). All cats with experimentally induced CKD had serum fPLI concentrations within the reference interval. CONCLUSIONS AND CLINICAL IMPORTANCE: Decreased renal function has a clinically relevant impact on serum fTLI concentrations and potentially could interfere with a diagnosis of exocrine pancreatic insufficiency (EPI). Serum fPLI concentration was not affected by experimentally induced CKD and thus serum fPLI may be used for the diagnosis of pancreatitis in cats with kidney disease. Additional studies are needed to verify these results in cats with naturally occurring CKD.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/34738673/